Uccello Mario, Boussios Stergios, Samartzis Eleftherios P, Moschetta Michele
Oncology Department, Northampton General Hospital NHS Trust, Northampton, UK.
Department of Medical Oncology, Medway NHS Foundation Trust, Gillingham, UK.
Ann Transl Med. 2020 Dec;8(24):1713. doi: 10.21037/atm.2020.04.15.
Malignant ovarian germ cell tumours (MOGCTs) are rare. Unlike epithelial ovarian cancer, MOGCTs typically occur in girls and young women. Fertility-sparing surgery and platinum-based chemotherapy remain the standard of care, providing high chance of cure at all stages. Given the lack of high-quality studies in this field, current practice guidelines recommend chemotherapy regimens adopted in testicular germ cell tumours. However, platinum-resistant/refractory MOGCTs retain a worse prognosis in comparison with their male counterpart. Herein, we focus on current systemic anti-cancer treatment options in MOGCTs and promising approaches. Future studies enrolling exclusively female participants or germ cell tumour trials allowing participation of MOGCT patients are strongly recommended in order to improve evidence on existing management and develop novel strategies.
恶性卵巢生殖细胞肿瘤（MOGCTs）较为罕见。与上皮性卵巢癌不同，MOGCTs通常发生于女孩和年轻女性。保留生育功能的手术和铂类化疗仍是标准治疗方案，在各个阶段都有很高的治愈几率。鉴于该领域缺乏高质量研究，目前的实践指南推荐采用睾丸生殖细胞肿瘤的化疗方案。然而，与男性同类肿瘤相比，铂耐药/难治性MOGCTs的预后更差。在此，我们重点关注MOGCTs目前的全身抗癌治疗选择和有前景的方法。强烈建议未来开展专门纳入女性参与者的研究或允许MOGCT患者参与的生殖细胞肿瘤试验，以完善现有治疗管理的证据并制定新策略。
